5 research outputs found
Perioperative in-stent thrombosis after lung resection performed within 3 months of coronary stenting
Background: Incidence of perioperative in-stent thrombosis associated with myocardial infarction in patients undergoing major lung resection within 3 months of coronary stenting. Methods: Retrospective multi-institutional trial including all patients undergoing major lung resection (lobectomy or pneumonectomy) within 3 months of coronary stenting with non-drug-eluting stents between 1999 and 2004. Results: There were 32 patients (29 men and 3 women), with age ranging from 46 to 82 years. One, two or four coronary stents were deployed in 72%, 22% and 6% of the patients, respectively. The time intervals between stenting and lung surgery were âȘ30 days, 30-60 days and 61-90 days in 22%, 53% and 25% of the patients, respectively. All patients had dual antiplatelet therapy after stenting. Perioperative medication consisted of heparin alone or heparin plus aspirin in 34% and 66% of the patients, respectively. Perioperative in-stent thrombosis with myocardial infarction occurred in three patients (9%) with fatal outcome in one (3%). Twenty patients underwent lung resection after 4 weeks of dual antiplatelet therapy as recommended by the ACC/AHA Guideline Update; however, two out of three perioperative in-stent thrombosis occurred in this group of patients. Conclusions: Major lung resection performed within 3 months of coronary stenting may be complicated by perioperative in-stent thrombosis despite 4 weeks of dual antiplatelet therapy after stenting as recommended by the ACC/AHA Guideline Updat
DĂ©mo de AMALD-serveur et AMALD-corpus, dĂ©diĂ©s Ă lâanalyse morphologique de lâallemand
Le projet AMALDarium vise Ă offrir sur la plateforme lingwarium.org (1) un service dâanalyse morphologique de lâallemand (AMALD-serveur), Ă grande couverture et de haute qualitĂ©, traitant la flexion, la dĂ©rivation et la composition, ainsi que les verbes Ă particule sĂ©parable sĂ©parĂ©e (ou agglutinĂ©e), (2) un corpus de rĂ©fĂ©rence de haute qualitĂ© donnant tous les rĂ©sultats possibles de lâanalyse morphologique, avant filtrage par une mĂ©thode statistique ou syntaxique, et (3) une plateforme (AMALD-Ă©val) permettant dâorganiser des Ă©valuations comparatives, dans la perspective dâamĂ©liorer les performances dâalgorithmes dâapprentissage en morphologie. Nous prĂ©sentons ici une dĂ©monstration en ligne seulement de AMALD-serveur et AMALD-corpus. Le corpus est un sous-ensemble anonymisĂ© et vĂ©rifiĂ© dâun corpus en allemand formĂ© de textes sur le cancer du sein, contenant de nombreux mots composĂ©s techniques
Several Ways to Use the Lingwarium.org Online MT Collaborative Platform to Develop Rich Morphological Analyzers
International audienc
Several ways to use the lingwarium.org online MT collaborative platform to develop rich morphological analyzers
We will demonstrate several morphological analyzers of languages for which morphological analysis is very difficult, and/or that are under-resourced. It will cover at least French, German, Khmer, Lao, Lithuanian, Portuguese, Quechua, Spanish and Russian. These morphological analyzers all run on the collaborative platform lingwarium.org that supports the ARIANE-H lingware development environment. Some will also be presented as stand-alone Windows applicationsTaikomosios informatikos katedraVytauto DidĆŸiojo universiteta
Convergence of patient- and physician-reported outcomes in the French National Registry of Facioscapulohumeral Dystrophy
International audienceFacioscapulohumeral muscular dystrophy (FSHD) is among the most prevalent muscular dystrophies and currently has no treatment. Clinical and genetic heterogeneity are the main challenges to a full comprehension of the physiopathological mechanism. Improving our knowledge of FSHD is crucial to the development of future therapeutic trials and standards of care. National FSHD registries have been set up to this end. The French National Registry of FSHD combines a clinical evaluation form (CEF) and a self-report questionnaire (SRQ), filled out by a physician with expertise in neuromuscular dystrophies and by the patient, respectively. Aside from favoring recruitment, our strategy was devised to improve data quality. Indeed, the pairwise comparison of data from 281 patients for 39 items allowed for evaluating data accuracy. Kappa or intra-class coefficient (ICC) values were calculated to determine the correlation between answers provided in both the CEF and SRQ. Results Patients and physicians agreed on a majority of questions common to the SRQ and CEF (24 out of 39). Demographic, diagnosis- and care-related questions were generally answered consistently by the patient and the medical practitioner (kappa or ICC values of most items in these groups were greater than 0.8). Muscle function-related items, i.e. FSHD-specific signs, showed an overall medium to poor correlation between data provided in the two forms; the distribution of agreements in this section was markedly spread out and ranged from poor to good. In particular, there was very little agreement regarding the assessment of facial motricity and the presence of a winged scapula. However, patients and physicians agreed very well on the Vignos and Brooke scores. The report of symptoms not specific to FSHD showed general poor consistency. Conclusions Patient and physician answers are largely concordant when addressing quantitative and objective items. Consequently, we updated collection forms by relying more on patient-reported data where appropriate. We hope the revised forms will reduce data collection time while ensuring the same quality standard. With the advent of artificial intelligence and automated decision-making, high-quality and reliable data are critical to develop top-performing algorithms to improve diagnosis, care, and evaluate the efficiency of upcoming treatments